Rechercher un essai clinique
Autre(s) option(s) de recherche
40 Résultat(s)
Essai en cours de recrutement = 
; Essai en cours = 
; Financé par un membre IRDiRC = 
Essai(s) clinique(s) national(aux)
ALLEMAGNE
Bayern
MÜNCHEN
PAOLA: A phase III, multicenter, randomized, parallel-group study to assess the efficacy and safety of double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg versus open-label Octreotide LAR or Lanreotide ATG in patients with inadequately controlled Acromegaly - DE - Completed
Medizinische Klinik und Poliklinik IV - Standort Ziemssenstraße
Medizinische Klinik und Poliklinik IV
ALLEMAGNE
Bayern
WÜRZBURG
Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant - Phase-IV-Study
Zentrum Innere Medizin (ZIM)
Medizinische Klinik und Poliklinik I - Endokrinologie und Diabetologie
ALLEMAGNE
Berlin
ADDRESS: NOT PROVIDED - DE
PRIMARYS: Phase IIIb, multicentre, open-label, single-arm study to assess the efficacy and safety of Lanreotide Autogel 120 mg administered every 28 days as primary medical treatment in Acromegalic patients with Macroadenoma - DE
Institution: Information not provided - DE
ALLEMAGNE
Berlin
BERLIN
CSOM230D2203: An open label, multicentre, single arm phase II study of Pasireotide LAR in patients with Rare Tumors of Neuroendocrine Origin - DE
Charité - Universitätsmedizin Berlin (CCM)
Medizinische Klinik für Endokrinologie und Stoffwechselmedizin
ALLEMAGNE
Hamburg
HAMBURG
Phase IIa, open label, dose ascending study to determine the maximum tolerated dose, safety and tolerability, pharmacokinetics and pharmacodynamics of a single dose of Lanreotide PRF in subjects with Acromegaly previously treated and controlled with Octreotide LAR - DE
UKE - Universitätsklinikum Hamburg-Eppendorf
III. Medizinische Klinik und Poliklinik
AUTRICHE
WIEN
WIEN
MPOWERED: A Phase 3, Randomized, Active Controlled Study to Evaluate Maintenance of Response, Safety and Patient Reported Outcomes in Acromegaly Patients Treated With Octreotide Capsules vs. Parenteral Somatostatin Receptor Ligands - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Endokrinologie und Stoffwechsel
BELGIQUE
ANTWERPEN
ANTWERPEN-EDEGEM
Phase IIa, open label, dose ascending study to determine the maximum tolerated dose, safety and tolerability, pharmacokinetics and pharmacodynamics of a single dose of Lanreotide PRF in subjects with Acromegaly previously treated and controlled with Octreotide LAR - BE
University and University Hospital of Antwerp - UZA
Antwerp University Hospital
BELGIQUE
LIEGE
LIEGE
Phase II, Open, Randomised, Parallel Group, Noncomparative Multicentre Study to Assess the Efficacy and Safety of Repeated Subcutaneous (S.C.) Administration of Different Doses of BIM 23A760 in Acromegalic Patients.
CHU Sart Tilman - Liège
Service d'Endocrinologie
BELGIQUE
LIEGE
LIEGE
Phase IIa, open label, dose ascending study to determine the maximum tolerated dose, safety and tolerability, pharmacokinetics and pharmacodynamics of a single dose of Lanreotide PRF in subjects with Acromegaly previously treated and controlled with Octreotide LAR - BE
CHU Sart Tilman - Liège
Service d'Endocrinologie
CANADA
Ontario
HAMILTON
FGFR Study: Proof-of-concept study of AZD 4547 in patients with FGFR1 or FGFR2 amplified tumours - UK
McMaster University
Department of Medicine
ESPAGNE
Castilla - León
SALAMANCA
Phase III, Open-Label, Multicenter International Study to Evaluate the Efficacy and Safety of an Octreotide Implant vs. Sandostatin LAR Depot in Patients With Acromegaly (completed)
Complejo Asistencial Universitario de Salamanca
Servicio de Hematología
ESPAGNE
Cataluña
BARCELONA
ESPORA - Observational study to evaluate, in acromegalic patients with disease persistence after surgery, those histopathologic, clinical, morphologic and biochemical factors predictors of hormonal control under somatostatin analogue treatment (Phase IV) (completed)
Hospital de la Santa Creu i Sant Pau
Servicio de Endocrinología y Nutrición
ESPAGNE
Cataluña
BARCELONA
A Phase II Randomised, Open-Label, Parallel Group Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Two Subcutaneous Dosing Regimens of ATL1103 in Adult Patients with Acromegaly - ES (Completed)
Hospital de la Santa Creu i Sant Pau
Servicio de Endocrinología y Nutrición
ESPAGNE
Comunidad Valenciana
ALZIRA
MPOWERED: A phase 3, randomized, open-label, active controlled, multicenter study to evaluate maintenance of response, safety and patient reported outcomes in acromegaly patients treated with octreotide capsules, and in patients treated with standard of care parenteral somatostatin receptor ligands [...] - ES
Hospital Universitario de La Ribera
Servicio de Endocrinología
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
PRIMARYS: Phase IIIb, Multicentre, Open-label, Single-arm, Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 mg Administered Every 28 Days as Primary Medical Treatment in Acromegalic Patients With Macroadenoma - ES (completed)
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
PAOLA - A phase III, multicenter, randomized, parallel-group study to assess the efficacy and safety of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open-label octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly - ES (Completed)
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin (Phase I-II) - ES (Completed)
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment (Phase IV) - ES
Institution: Information not provided - ES
ESPAGNE
País Vasco
BARAKALDO
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly (Phase III) - ES (Completed)
Hospital Universitario Cruces - Osakidetza
Investigación en Genética y Control de Diabetes y Enfermedades Endocrinas
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Etude de Phase II, multicentrique, randomisée, en ouvert, non comparative, groupes parallèles, évaluant l'efficacité et la tolérance de l'administration répétée sous-cutanée (s.c.) de différentes doses de BIM 23A760 chez des patients acromégales
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
PAOLA - Etude multicentrique de phase III, randomisée, en groupes parallèles, évaluant l'efficacité et la tolérance du pasiréotide LP 40 mg et 60 mg en double aveugle versus la poursuite d'octréotide LP 30 mg ou de lanréotide Autogel (ATG) 120 mg en ouvert chez des patients ayant une acromégalie insuffisamment contrôlée.
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly (Phase III) - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
PRIMARYS: Phase IIIb, Multicentre, Open-label, Single-arm, Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 mg Administered Every 28 Days as Primary Medical Treatment in Acromegalic Patients With Macroadenoma - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Etude de phase IIIb multicentrique, en ouvert, à bras unique pour évaluer l'éfficacité et la tolérance des pasiréotide chez des patients atteints d'acromégalie et insuffisamment contrôlés avec la première génération d'analogue de la somatostatine.
Institution: Information not provided - FR
FRANCE
NOUVELLE AQUITAINE
PESSAC
Etude de phase IIa, ouverte, de dose croissante, permettant de déterminer la dose maximale tolérée, la sécurité et la tolérance, la pharmacocinétique et la pharmacodynamique d'une dose unique de lanréotide PRF chez des patients atteints d'acromégalie préalablement controllés et traités par l'octréotide LAR.
CHU de Bordeaux-GH Sud - Hôpital Haut-Lévêque
Service d'endocrinologie-diabétologie et maladies métaboliques
GRECE
ATTIKI
ATHENS
A study to compare the efficacy and PEGA-0435 safety of Pegvisomant to that of sandostatin LAR in patients with acromegaly (Phase IV)
Evangelismos general hospital
Hormonal laboratory (Director Prof. Nikolaos Thalassinos)
GRECE
ATTIKI
ATHENS
Observational study in patients with acromegaly on octreotide treatment
Evangelismos general hospital
Hormonal laboratory (Director Prof. Nikolaos Thalassinos)
ITALIE
TOSCANA
SIENA
Phase IIa, Open Label, Dose Ascending Study to Determine the Maximum Tolerated Dose, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Lanreotide PRF in Subjects With Acromegaly Previously Treated and Controlled With Octreotide LAR-IT
Azienda Ospedaliera Universitaria Senese - Ospedale Santa Maria alle Scotte
U.O.C. di Endocrinologia
PAYS-BAS
Zuid-Holland
ROTTERDAM
Phase IIa, open label, dose ascending study to determine the maximum tolerated dose, safety and tolerability, pharmacokinetics and pharmacodynamics of a single dose of Lanreotide PRF in subjects with Acromegaly previously treated and controlled with either Ocreotide LAR or Lanreotide Autogel - NL
Erasmus MC - Erasmus Medisch Centrum
Polikliniek Endocrinologie
ROYAUME-UNI
Greater London
LONDON
Phase IIa, Open Label, Dose Ascending Study to Determine the Maximum Tolerated Dose, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Lanreotide PRF in Subjects With Acromegaly Previously Treated and Controlled With Octreotide LAR-UK
Barts and The London School of Medicine and Dentistry
William Harvey Research Institute
ROYAUME-UNI
Greater Manchester
ADDRESS: NOT PROVIDED - UK
CCRN 704: Efficacy and safety of oral Octreolin in patients with acromegaly who are currently receiving parenteral somatostatin analogs (Phase III) - UK
Institution: Information not provided - UK
ROYAUME-UNI
Greater Manchester
ADDRESS: NOT PROVIDED - UK
Phase III, multicentre, open study to assess the efficacy and safety profiles of the co-administration of lanreotide Autogel 120 mg (administered via deep subcutaneous injections every 28 days) and pegvisomant 40 to 120 mg per week (administered via subcutaneous route once or twice a week) in acromegalic patients failing to respond to lanreotide Autogel 120 mg - UK
Institution: Information not provided - UK
ROYAUME-UNI
Greater Manchester
ADDRESS: NOT PROVIDED - UK
An Open-Label Phase I/IIa Study of Intravenous BAL101553 in Adult Patients with Advanced Solid Tumors
Institution: Information not provided - UK
ROYAUME-UNI
Greater Manchester
ADDRESS: NOT PROVIDED - UK
Phase IIIb, Multicentre, Open-label, Single-arm, Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 mg Administered Every 28 Days as Primary Medical Treatment in Acromegalic Patients With Macroadenoma - UK
Institution: Information not provided - UK
ROYAUME-UNI
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A multicenter, randomized, blinded study to assess the safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly (Phase III) - UK
Institution: Information not provided - UK
ROYAUME-UNI
Greater Manchester
MANCHESTER
1103-CT02 - A Phase II Randomised, Open-Label, Parallel Group Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Two Subcutaneous Dosing Regimens of ATL1103 in Adult Patients with Acromegaly - UK
Christie Hospital
Department of Endocrinology
ROYAUME-UNI
Greater Manchester
MANCHESTER
Phase IIa, Open Label, Dose Ascending Study to Determine the Maximum Tolerated Dose, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Lanreotide PRF in Subjects With Acromegaly Previously Treated and Controlled With Octreotide LAR-UK
Christie Hospital
Department of Endocrinology
ROYAUME-UNI
Oxfordshire
OXFORD
Phase IIa, Open Label, Dose Ascending Study to Determine the Maximum Tolerated Dose, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Lanreotide PRF in Subjects With Acromegaly Previously Treated and Controlled With Octreotide LAR-UK
The Churchill Hospital
Oxford Centre for Diabetes, Endocrinology and Metabolism
ROYAUME-UNI
Surrey
LONDON
PAOLA - A phase III, multicenter, randomized, parallel-group study to assess the efficacy and safety of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open-label octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly - UK
Novartis Pharmaceuticals
Medical Collaboration Centre
Essai(s) clinique(s) multinational(aux)
FRANCE
ILE-DE-FRANCE
BOULOGNE-BILLANCOURT